Professor Georgina Long hands on baton of SMR Presidency
31 October 2020
MIA’s Co-Medical Director, Professor Georgina Long AO, has passed the baton after two years as President of the Society for Melanoma Research (SMR). The US-based SMR is the world’s largest association of melanoma researchers and scientists. Professor Long was the first Australian and first female President of SMR, her election testament to her international standing as one of the world’s pre-eminent melanoma clinicians and researchers.
The annual 2020 SMR Melanoma Congress, scheduled to be held in New Orleans, was postponed due to the impact of COVID-19. Instead, a Virtual Congress was held during which Professor Long handed over the Presidency to Professor Ashani Weeraratna from Johns Hopkins School of Medicine.
In a message to SMR members, Professor Long said, ‘ The COVID-19 pandemic has presented a major challenge for all of us across the world, and we stand united in limiting the impact of the virus on our health, productivity and goals.’
Professor Long cites as a highlight of her 2-year Presidency, the phenomenal research output by SMR members who have continued to lead the cancer field despite the impact of COVID-19.
‘Despite not being able to gather in person, as we usually do annually, we connected virtually from around the world to share our knowledge and continue our collaboration,’ Professor Long said. ‘Importantly, we highlighted the work of two fabulous researchers in the field who both received SMR Awards for their contributions – Stefani Spranger was awarded the Young Investigator Award and Yardena Samuels was awarded the Estela Medrano Award.
‘It has been an honour to lead SMR for the past two years, and I look forward to continued collaboration as we move ever closer to reaching our goal of zero deaths from melanoma,’ she said.
Australian researchers have successfully trialled a combination of new treatments to prevent melanoma from spreading to distant organs.
A new treatment that combines an antibody with a cancer-killing virus improves outcomes for patients with advanced melanoma, an international clinical trial has shown.
It feels like groundhog day - another reality TV show, another batch of blatantly sunburnt contestants.
Wouldn’t it be great if your doctor could know if you would respond to treatment before you even had it?
In our latest research update we showcase research in survival estimates, uncover biomarkers, and reveal practice-changing research in surgery and medical oncology.
Senior Clinical Trial Coordinators, like Sarah Lane, support melanoma patients throughout the clinical trial process.
Melanomas are often hard to differentiate from moles. But new technology is helping to improve accuracy of diagnosis.
We are excited to announce that SunSense will proudly be an official supporter of Melanoma Institute Australia. SunSense is an Australian, family owned business.
Five years ago Julie Randall was diagnosed with melanoma and was given months to live. The melanoma had spread throughout her body. The doctors said it was incurable and she’d be lucky if she survived the next nine months. Julie, a patient at Melanoma Institute Australia under Professor Georgina Long was placed on an experimental drug trial. To watch the entire program, visit 9now.com or click here.
Meet our latest Surgical Oncology Fellow, Eva Nagy, to find out more about life as a surgical oncologist, why she came to MIA and what she hopes to achieve.
Melanoma research at ASCO this year focussed on the more precise use of current treatments to ensure optimal treatment for each patient.
MIA recently demonstrated that reflectance confocal microscopy is a useful tool in the clinic to diagnose suspicious-looking lesions in the mouth.
New research is likely to change the way melanoma is managed in many patients by reducing the need for major surgery and its associated morbidity and cost.
Researchers from MIA will present their latest research findings to the world’s largest oncology conference in early June.
Australian researchers pioneer life-extending treatment for advanced melanoma patients with brain tumours
Australian researchers are the first to demonstrate that patients with advanced melanoma which has spread to the brain can have increased life expectancy and possibly even beat the disease.
Melanoma March 2017 - that's a wrap! Thank you to everyone that helped make it happen.
Thank you so much to all those who contributed in a variety of ways to Melanoma March 2017 in 17 different locations and more around the country! You have contributed to getting the Big Data for Melanoma national Research Project happening!
By looking at the ‘dark matter’ of the genome, new research has found that genetic changes in acral and mucosal melanoma are completely different to mutations found in skin melanoma.
‘Slip, slop, slap’ is synonymous with being Australian and playing it safe in the sun. These sun smart rules reduce our chances of getting melanoma of the skin. However, new research tells a different story for those affected by rarer forms of melanoma.